ClinicalTrials.gg
CompletedNCT03470038Updated Feb 15, 2019

Interaction Between NGF and Acute Exercise-induced Ischemia

An Early Phase 1 interventional study of NGF and Isotonic saline in Hyperalgesia, Pain Response and Healthy Subjects, sponsored by Aalborg University. Completed at 1 site in Denmark. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-02-15.

Sponsored by Aalborg University · Early Phase 1, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
21
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 17 studies in Hyperalgesia with a site in Denmark — none open to participants now, none under way, none of them phase 3. Hyperalgesia · Denmark.

Enrollment
9th of 15
21 · median 23
Started
2018
the only one that year
Phase 1
4 of 17
none open now
Registered
16th of 17
by date
Lead sponsor
4 of 17
Aalborg University

Among the 17 studies in Hyperalgesia with a site in Denmark, this one is the 9th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2018, is one of 4 in phase 1, and was the 16th registered.

Hyperalgesia

166 studies on the registry are indexed under Hyperalgesia; 13 are open to participants now.

Browse Hyperalgesia studies →

Open to participants now

None of the 17 studies in Hyperalgesia with a site in Denmark is open now. The open studies under Hyperalgesia, anywhere →

Who these studies take

Of the 7 Hyperalgesia studies recruiting now, 4 set no upper age limit and 1 stops at 75 or younger; 2 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies in Hyperalgesia with a site in Denmark as a file.
02

Study summary

The purpose of this study is to investigate pain evoked responses and facilitation of NGF-induced mechanical muscle hyperalgesia over time following an acute exercised-induced ischemic condition in a NGF-sensitized muscle.

Read the detailed description

Assessing evoked pain responses and muscle hyperalgesia following contractions during acute ischemia in a NGF-sensitized muscle may clarify whether an interaction between NGF sensitization and acidic stimulation exist.

It is hypothesized that acute ischemic exercise with the NGF-sensitized TA muscle, in contrast to ischemic exercise in a non-sensitized would: 1) potentiate pain-evoked responses, and 2) facilitate NGF-induced muscle hyperalgesia.

03

Conditions studied

  • Hyperalgesia
  • Pain Response
  • Healthy Subjects

Browse trials for

Keywords

  • NGF-induced pain
  • Ischemia-induced pain
  • Hyperalgesia
  • NGF pain model
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy and pain free volunteers

Exclusion criteria

Exclusion Criteria:

  • Pregnancy
  • Drug addiction defined as the use of cannabis, opioids or other drugs
  • Previous neurologic, mental illnesses, or psychiatric diseases.
  • Past history of chronic pain in the musculoskeletal system (muscle, joint, cartilage, connective tissue)
  • Participation in other pain trials throughout the study period
  • Lack of ability to cooperate
  • Taking any analgesic 24 hours before the injections
  • Performing any strenuous leg exercise through out the study period causing sore muscles
05

Study design

Phase
Early Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    NGF condition + Control condition

    All participants will receive five injections with NGF (1ug/0.5ml) into the tibialis anterior muscle in their non-dominant leg After 4 weeks: All participants will receive five injections with isotonic saline (9%/0.5ml) into the tibialis anterior muscle in their non-dominant leg

    Drug: NGF · Drug: Isotonic saline

  • Experimental
    Control condition + NGF condition

    All participants will receive five injections with isotonic saline (9%/0.5ml) into the tibialis anterior muscle in their non-dominant leg After 4 weeks: All participants will receive five injections with NGF (1ug/0.5ml) into the tibialis anterior muscle in their non-dominant leg

    Drug: NGF · Drug: Isotonic saline

Interventions

06

What researchers measure

Primary outcomes

  1. Muscle sensitivity

    Pressure pain thresholds (PPTs) are assessed over the non-dominant tibialis anterior muscle using a handhold pressure algometer.

    Time frame: Change from baseline at 1 week

Secondary outcomes

  1. Ischemic-induced pain intensity

    Subjects perform 45 dorsiflexions with their non-dominant leg while a cuff is mounted over the knee to occlude the blodflow from the muscle (ischemia) Subjects subsequently rate their perceived pain intensity verbally on a numeric rating scale (NRS)

    Time frame: Assessed right after the dorsiflexions have been performed

  2. Functional muscle pain

    Subjects evaluate their muscle pain during movement using a Likert Scale for lower limp

    Time frame: Change from baseline at 1 week

  3. Muscle pain diary

    Subjects evaluate their muscle pain during movement using a Likert Scale for lower limp and perceived pain intensity at rest on a numeric rating scale (NRS). The diary is filled out at home on days between sessions

    Time frame: Change from baseline at 1 week

07

Study locations

1 site
  • Aalborg University
    Aalborg, 9220, Denmark
08

References and documents

Publications

  • Sorensen LB, Gazerani P, Graven-Nielsen T. Nerve growth factor-induced muscle hyperalgesia facilitates ischaemic contraction-evoked pain. Eur J Pain. 2019 Nov;23(10):1814-1825. doi: 10.1002/ejp.1455. Epub 2019 Aug 5. Erratum In: Eur J Pain. 2020 Feb;24(2):470-472. doi: 10.1002/ejp.1517. PubMed 31314952 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2018 to primary completion in May 2018, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2018
First posted
Mar 19, 2018
StartActual
Mar 15, 2018
Primary completionActual
May 15, 2018
CompletionActual
Jun 15, 2018
Last update
Feb 15, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 15, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03470038
Lead sponsor
Aalborg University
Responsible party
Line Bay Sørensen (PhD. stud., Aalborg University) — Principal investigator
First posted
Mar 19, 2018
Start date
Mar 15, 2018
Primary completion
May 15, 2018
Completion
Jun 15, 2018
Last update
Feb 15, 2019

Study contacts

Line Bay Sørensen, Ph.d stud.
principal investigator · Aalborg University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nerve Growth Factor

Start the discussion